Adage Capital Partners
KZR

Adage Capital Partners’s Kezar Life Sciences KZR Stock Holding History

Adage Capital Partners’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,000
Closed -$1.72M – 1018
2022
Q3 		$1.72M Sell
20,000
-28,000
-58% -$2.72M ﹤0.01% 864
2022
Q2 		$3.97M Sell
48,000
-138,485
-74% -$12.2M 0.01% 826
2022
Q1 		$31M Sell
186,485
-19,182
-9% -$2.75M 0.06% 332
2021
Q4 		$34.4M Buy
+205,667
New +$23.2M 0.06% 318

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Adage Capital Partners's KZR Position: Q4 2022 in Review

Adage Capital Partners sold out of Kezar Life Sciences (KZR) in Q4 2022, closing a stake of 20,000 shares — an estimated $1.72M sold.

Adage Capital Partners first reported a position in KZR in Q4 2021 and held it in 4 quarters. The position peaked at $34.4M in Q4 2021. 123 funds tracked by Wall St. Rank hold KZR as of Q4 2022.

  • Adage Capital Partners reported no remaining Kezar Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Adage Capital Partners sold 20,000 Kezar Life Sciences shares in Q4 2022, an estimated $1.72M.
  • Adage Capital Partners first reported a position in Kezar Life Sciences in Q4 2021 and held it in 4 quarters.
  • Adage Capital Partners's Kezar Life Sciences position peaked at $34.4M in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2022.

Based on Adage Capital Partners's 13F filing for Q4 2022, filed 14 Feb 2023.